Biorce 🇪🇸
AI platform that streamlines the clinical trial lifecycle, from protocol design and feasibility to regulatory submissions.
About Biorce
Biorce develops Aika, a unified operating system designed to streamline the clinical trial process by leveraging AI for protocol creation, feasibility assessments, and regulatory compliance. This platform integrates clinical intelligence and data analysis to enhance efficiency, reduce costs, and accelerate timelines across all phases of clinical development.
Biorce is a Spain-based company founded in 2024, now around 206 people. It has raised $61.6M in disclosed funding. FundFinder classes it as AI & ML.
Founded by Clara Bernardes (Co-Founder & Chief Scientific Officer; previously AIXIAL GROUP, AOP Health; Coventry University), Diogo Pisoeiro (Co-Founder & Chief Product Officer; previously Finest Station, Freelancer; Elisava Barcelona School of Design and Engineering), Pedro Coelho (Founder / CEO; previously Konspol Holding, Talentmark; EU Business School, Geneva).
Its investors also appear on FundFinder's most-active lists for Series A · Climate & Sustainability (53 funds), Series A · Generalist (64 funds), Series A · Healthcare & Wellbeing (54 funds).
Company facts from Harmonic and public filings; team backgrounds from public profiles. Refreshed weekly.
Series A · Feb 2026
- Mustard Seed MAZE — Investing in the great businesses of the future, those that solve social and environmental challenges. · cheques £100k – £1M
- Norrsken VC — Norrsken VC is a Stockholm-based impact VC fund investing in start-ups solving the world's biggest problems while building massive businesses · cheques £1M – £15M